Prosecution Insights
Last updated: October 02, 2026
Application No. 18/556,564

PROTEASE INHIBITORS AND METHODS OF USE

Final Rejection §102§112
Filed
Oct 20, 2023
Priority
Apr 21, 2021 — provisional 63/177,475 +2 more
Examiner
BARSKY, JARED
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Cleveland Clinic Foundation
OA Round
2 (Final)
50%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
474 granted / 944 resolved
-9.8% vs TC avg
Strong +23% interview lift
Without
With
+22.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
66 currently pending
Career history
1021
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
48.9%
+8.9% vs TC avg
§102
8.5%
-31.5% vs TC avg
§112
16.9%
-23.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 944 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendments Applicant’s amendments to the claims of June 9, 2026, in response to the Office Action of March 10, 2026 are acknowledged. Response to Arguments Applicant’s amendments to the claims render the rejections of record moot. As such, prior art is applied below as necessitated by the amendments to the claims. Status of the Claims Claims 1, 20, 22, 24, 37-40, 43, 46, and 48-56 are pending and examined. Allowable Subject Matter Claims 20, 22, 24, 37-40, 43, 46, 50, 51, and 53-56 are allowed. Claim Rejections - 35 USC § 112 Claim 52 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 1 does not provide for R1 to be a 4 or 5 membered heterocycle. Rather, Applicant argues that thiophene along with other heterocycles are excluded. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 52 depends from claim 1 and includes multiple 5 membered heterocycles in the position of R1. These are therefore not further limiting. In examples, R1 includes the following 5-membered heterocycle. PNG media_image1.png 124 146 media_image1.png Greyscale . As such, claim 52 is not further limiting of claim 1. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 48, and 49 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS STN RN 1014250-37-3 (2008) (shown below). PNG media_image2.png 362 426 media_image2.png Greyscale This is a compound of formula (II), wherein R5 is hydrogen; R1 is phenyl. As such, claims 1, 48, and 49 are anticipated by the prior art. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS STN RN 1795027-54-1 (2015) (shown below). PNG media_image3.png 354 428 media_image3.png Greyscale As such, claim 1 is anticipated by the prior art. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JARED D. BARSKY whose telephone number is (571)-272-2795. The examiner can normally be reached on Monday through Friday from 8:30 to 5:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy L. Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JARED BARSKY/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Oct 20, 2023
Application Filed
Mar 10, 2026
Non-Final Rejection mailed — §102, §112
Jun 09, 2026
Response Filed
Sep 09, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740947
METHOD OF INITIATING SOTALOL HYDROCHLORIDE DOSING
3y 4m to grant Granted Sep 22, 2026
Patent 12741958
CRYSTAL FORM OF PYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR
2y 9m to grant Granted Sep 22, 2026
Patent 12723018
CINNAMOYL AMINO ACID COMPOUND AND USE THEREOF
3y 11m to grant Granted Sep 01, 2026
Patent 12721826
SALT OF A PHARMACEUTICAL COMPOUND
1y 4m to grant Granted Sep 01, 2026
Patent 12708607
THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS
3y 7m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
50%
Grant Probability
73%
With Interview (+22.7%)
2y 7m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 944 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month